Preparation of Deferasirox in nano-scale by ultrasonic irradiation and optimization the amount and reaction time parameters

International Journal of Nano Dimension

مقاله 5، دوره 6، شماره 4، دی 2015، صفحه 363-369   

نوع مقاله: Reasearch Paper

شناسه دیجیتال (DOI): 10.7508/ijnd.2015.04.004

نویسندگان

M. Khatamifar؛ Z. Rashidi Ranjbar؛ S. J. Fatemi^*

Department of Chemistry, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.

چکیده

This work reports a facile sonochemical route in the synthesis of nano particle of deferasirox for the first time. One application of nanotechnology is in improvement of available treatments for various diseases. Deferasirox (ICL670 or Exjade) is a tridentate chelating agent for removing transfusion overload iron in thalassemia patients. In the present work, deferasirox was prepared in nano size by using of ultrasound waves. The effects of amount and reaction time on the size of deferasirox were investigated. These parameters were optimized at various amounts and different reaction times. Fourier transform infrared spectroscopy (FT-IR) and X-ray diffraction (XRD) studies show that the deferasirox in nature structure does not change during the reaction. The results show that the finest particle is related to the following conditions: 45min, time reaction and 0.1g, amount of deferasirox. Therefore, the ultrasonic bath method has a fundamental role in the preparation of deferasirox in nano scale. This method is simple, relatively fast and low cost.

کلیدواژه‌ها

Nano drug؛ Deferasirox؛ Iron chelators؛ Bath ultrasound؛ Fast synthesis؛ High absorption

مراجع

[1]      Asghari I., Esmaeilzadeh F., (2012), Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach Int. J. pharm. 433: 149-156.

[2]      Kawabata Y., Wada K., Nakatani M., Yamada S., Onoue S., (2011), Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J. pharm. 420: 1-10.

[3]      Sekhon B., Kamboj S., (2010). Inorganic nanomedicine- Part 1. Int. J. Nanomedicine. 6: 516-522.

[4]      Liu L., Wen J., Yang Y., Tan W., (2013), Ultrasound field distribution and ultrasonic oxidation desulfurization efficiency. Ultrason. Sonochem. 20: 696-702.

[5]      Rohani Bastami T., Entezari M., (2012), A novel approach for the synthesis of superparamagnetic Mn3O4 nanocrystals by ultrasonic bath. Ultrason Sonochem. 19: 560-569.

[6]      Song Y. L., Dong Y. F., Wu F., Yang T., Yang G. L., (2015), One-pot three-component synthesis of 3-hydroxy-5,5-dimethyl-2-[phenyl(phenylthio)methyl]cyclohex-2-enone derivatives under ultrasound. Ultrason Sonochem. 22: 119-124.

[7]      Gedanken A., (2004), Using sonochemistry for the fabrication of nanomaterials. Ultrason Sonochem. 11: 47–55.

[8]      Saljooghi A., Fatemi J., (2011), Removal of thallium by deferasirox in rats as biological model. J Appl. Toxicol. 31: 139-143.

[9]      Saljooghi A. S., Fatemi S. J., (2010), Clinical evaluation of Deferasirox for removal of cadmium ions in rat. Biometals. 23: 707-712.

[10]  Nejad F. K., Fatemi S. J., Sheibani V., (2013), An investigation of cobalt toxicity on blood parameters and evaluation of deferasirox and desferrioxamine chelators in removing cobalt from biological system. Toxin Rev. 56: 1-7.

[11]  Lindsey W. T., Olin B. R., (2007), New drug, deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 29: 2145-2166.

[12]  Yang L. P. H., Keam S. J., Keating G. M., (2007), Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs. 67: 2211-2230.

[13]  Heinz U., Hegetschweiler K., Acklin P., Faller B., Lattmann R., Schnebli H. P., (1999), 4-[3,5-bis(2-hydroxyphenyl)-1,2,4- triazol-1-yl]-benzoic acid: a novel efficient and selective iron (III) complexing agent. Angew. Chem. Int. Ed. 38: 2568-2570.

[14]  Cappellini M. D., (2008), Long-term efficacy and safety of deferasirox. Blood Review. 2: 35-41.

[15]  Steinhauser S., Heinz U., Bartholoma M., Weyhermu¨ller T., Nick H., Hegetschweiler K., (2004), Complex formation of ICL670 and related ligands with FeIII and FeII. Eur. J. Inorg. Chem. 21: 4177-4192.

[16]  Wood J. C., Otto-Duessel M., Gonzalez I., Aguilar M. I., Shimada H., Nick H., (2006), Deferasirox and deferiprone remove cardiac iron in the iron overloaded gerbil. Transl. Res. 148: 272-280.

[17]  Thomas S., Joshi S. Ch., Vir D., Agarwal A., (2012), Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC–ESI–QT/MS/MS. J. Pharm. Biomed. Anal. 63: 112-119

[18]  Fatemi S. J., Khajoee nejad F., Zandevakili T., (2014), Chelation of cobalt by combining deferasirox, deferiprone and desferrioxamine in rats. Toxin Rev.: 55: 1-5.

[19]  Fatemi S. J., Shokooh Saljooghi A., Dahooee Balooch F., (2011), Chelation of cadmium by combining deferasirox and deferiprone in rats. Toxicol. Ind. Health. 27: 371-377.